Cholesterol starvation induces differentiation of human leukemia HL-60 cells. 2007

Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
Servicio de Bioquímica-Investigación, Hospital Ramón y Cajal, and CIBER Fisología Obesidad y Nutrición (CB06/03), Instituto de Salud Carlos III, Madrid, Spain.

Cholesterol metabolism is particularly active in malignant, proliferative cells, whereas cholesterol starvation has been shown to inhibit cell proliferation. Inhibition of enzymes involved in cholesterol biosynthesis at steps before the formation of 7-dehydrocholesterol has been shown to selectively affect cell cycle progression from G(2) phase in human promyelocytic HL-60 cells. In the present work, we explored whether cholesterol starvation by culture in cholesterol-free medium and treatment with different distal cholesterol biosynthesis inhibitors induces differentiation of HL-60 cells. Treatment with SKF 104976, an inhibitor of lanosterol 14-alpha demethylase, or with zaragozic acid, which inhibits squalene synthase, caused morphologic changes alongside respiratory burst activity and expression of cluster of differentiation antigen 11c (CD11c) but not cluster of differentiation antigen 14. These effects were comparable to those produced by all-trans retinoic acid, which induces HL-60 cells to differentiate following a granulocyte lineage. In contrast, they differed from those produced by vitamin D(3), which promotes monocyte differentiation. The specificity of the response was confirmed by addition of cholesterol to the culture medium. Treatment with PD 98059, an inhibitor of extracellular signal-regulated kinase, abolished both the activation of NADPH oxidase and the expression of the CD11c marker. In sharp contrast, BM 15766, which inhibits sterol Delta(7)-reductase, failed to induce differentiation or arrest cell proliferation. These results show that changes in the sterol composition may trigger a differentiation response and highlight the potential of cholesterol pathway inhibition as a possible tool for use in cancer therapy.

UI MeSH Term Description Entries
D007810 Lanosterol A triterpene that derives from the chair-boat-chair-boat folding of 2,3-oxidosqualene. It is metabolized to CHOLESTEROL and CUCURBITACINS. Kryptosterol,4,4,14 alpha-trimethyl-5 alpha-cholesta-8,24-dien-3 beta-ol
D010088 Oxidoreductases The class of all enzymes catalyzing oxidoreduction reactions. The substrate that is oxidized is regarded as a hydrogen donor. The systematic name is based on donor:acceptor oxidoreductase. The recommended name will be dehydrogenase, wherever this is possible; as an alternative, reductase can be used. Oxidase is only used in cases where O2 is the acceptor. (Enzyme Nomenclature, 1992, p9) Dehydrogenases,Oxidases,Oxidoreductase,Reductases,Dehydrogenase,Oxidase,Reductase
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D002784 Cholesterol The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils. Epicholesterol
D003577 Cytochrome P-450 Enzyme System A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism. Cytochrome P-450,Cytochrome P-450 Enzyme,Cytochrome P-450-Dependent Monooxygenase,P-450 Enzyme,P450 Enzyme,CYP450 Family,CYP450 Superfamily,Cytochrome P-450 Enzymes,Cytochrome P-450 Families,Cytochrome P-450 Monooxygenase,Cytochrome P-450 Oxygenase,Cytochrome P-450 Superfamily,Cytochrome P450,Cytochrome P450 Superfamily,Cytochrome p450 Families,P-450 Enzymes,P450 Enzymes,Cytochrome P 450,Cytochrome P 450 Dependent Monooxygenase,Cytochrome P 450 Enzyme,Cytochrome P 450 Enzyme System,Cytochrome P 450 Enzymes,Cytochrome P 450 Families,Cytochrome P 450 Monooxygenase,Cytochrome P 450 Oxygenase,Cytochrome P 450 Superfamily,Enzyme, Cytochrome P-450,Enzyme, P-450,Enzyme, P450,Enzymes, Cytochrome P-450,Enzymes, P-450,Enzymes, P450,Monooxygenase, Cytochrome P-450,Monooxygenase, Cytochrome P-450-Dependent,P 450 Enzyme,P 450 Enzymes,P-450 Enzyme, Cytochrome,P-450 Enzymes, Cytochrome,Superfamily, CYP450,Superfamily, Cytochrome P-450,Superfamily, Cytochrome P450
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D058886 Sterol 14-Demethylase An NADPH-dependent P450 enzyme that plays an essential role in the sterol biosynthetic pathway by catalyzing the demethylation of 14-methyl sterols such as lanosterol. The enzyme acts via the repeated hydroxylation of the 14-methyl group, resulting in its stepwise conversion into an alcohol, an aldehyde and then a carboxylate, which is removed as formic acid. Sterol 14-demethylase is an unusual cytochrome P450 enzyme in that it is found in a broad variety of organisms including ANIMALS; PLANTS; FUNGI; and protozoa. Sterol 14-Demethylases,CYP51 Cytochrome P-450,Cytochrome P-450 CYP51,Eburicol 14 alpha-Demethylase,Eburicol 14alpha-Demethylase,Lanosterol 14 alpha-Demethylase,Obtusifoliol 14alpha-Demethylase,Sterol 14-alpha-Demethylase,14 alpha-Demethylase, Eburicol,14 alpha-Demethylase, Lanosterol,14-Demethylase, Sterol,14-Demethylases, Sterol,14-alpha-Demethylase, Sterol,14alpha-Demethylase, Eburicol,14alpha-Demethylase, Obtusifoliol,CYP51 Cytochrome P 450,CYP51, Cytochrome P-450,Cytochrome P 450 CYP51,Cytochrome P-450, CYP51,Eburicol 14 alpha Demethylase,Eburicol 14alpha Demethylase,Lanosterol 14 alpha Demethylase,Obtusifoliol 14alpha Demethylase,P-450 CYP51, Cytochrome,P-450, CYP51 Cytochrome,Sterol 14 Demethylase,Sterol 14 Demethylases,Sterol 14 alpha Demethylase
D018922 HL-60 Cells A promyelocytic cell line derived from a patient with ACUTE PROMYELOCYTIC LEUKEMIA. HL-60 cells lack specific markers for LYMPHOID CELLS but express surface receptors for FC FRAGMENTS and COMPLEMENT SYSTEM PROTEINS. They also exhibit phagocytic activity and responsiveness to chemotactic stimuli. (From Hay et al., American Type Culture Collection, 7th ed, pp127-8) HL60 Cells,Cell, HL60,Cells, HL60,HL 60 Cells,HL-60 Cell,HL60 Cell
D020935 MAP Kinase Signaling System An intracellular signaling system involving the mitogen-activated protein kinase cascades (three-membered protein kinase cascades). Various upstream activators, which act in response to extracellular stimuli, trigger the cascades by activating the first member of a cascade, MAP KINASE KINASE KINASES; (MAPKKKs). Activated MAPKKKs phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES which in turn phosphorylate the MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs). The MAPKs then act on various downstream targets to affect gene expression. In mammals, there are several distinct MAP kinase pathways including the ERK (extracellular signal-regulated kinase) pathway, the SAPK/JNK (stress-activated protein kinase/c-jun kinase) pathway, and the p38 kinase pathway. There is some sharing of components among the pathways depending on which stimulus originates activation of the cascade. MAP Kinase Cascade,MAP Kinase Module,MAP Kinase Signaling Cascade,MAP Kinase Signaling Pathway,MAP Kinase Signaling Pathways,ERK Pathway,ERK Signal Tranduction Pathway,ERK1 and ERK2 Pathway,ERK1-2 Pathway,JNK Pathway,JNK Signaling Pathway,MAP Kinase Modules,MAP Kinase Signaling Cascades,MEK-ERK Pathway,p38 Kinase Pathway,p38 Kinase Signaling Pathway,Cascade, MAP Kinase,ERK Pathways,ERK1 2 Pathway,ERK1-2 Pathways,JNK Pathways,JNK Signaling Pathways,Kinase Cascade, MAP,Kinase Pathway, p38,Kinase Pathways, p38,MAP Kinase Cascades,MEK ERK Pathway,MEK-ERK Pathways,Module, MAP Kinase,Pathway, ERK,Pathway, ERK1-2,Pathway, JNK,Pathway, JNK Signaling,Pathway, MEK-ERK,Pathway, p38 Kinase,Pathways, ERK,Pathways, ERK1-2,Pathways, JNK,Pathways, JNK Signaling,Pathways, MEK-ERK,Pathways, p38 Kinase,Signaling Pathway, JNK,Signaling Pathways, JNK,p38 Kinase Pathways
D065607 Cytochrome P-450 Enzyme Inhibitors Drugs and compounds which inhibit or antagonize the biosynthesis or actions of CYTOCHROME P-450 ENZYMES. Cytochrome P-450 Inhibitors,Cytochrome P-450 Monooxygenase Inhibitors,Cytochrome P-450 Oxygenase Inhibitors,Cytochrome P-450-Dependent Monooxygenase Inhibitors,P-450 Enzyme Inhibitors,P450 Enzyme Inhibitors,Cytochrome P 450 Dependent Monooxygenase Inhibitors,Cytochrome P 450 Enzyme Inhibitors,Cytochrome P 450 Inhibitors,Cytochrome P 450 Monooxygenase Inhibitors,Cytochrome P 450 Oxygenase Inhibitors,Enzyme Inhibitors, P-450,Enzyme Inhibitors, P450,Inhibitors, Cytochrome P-450,Inhibitors, P-450 Enzyme,Inhibitors, P450 Enzyme,P 450 Enzyme Inhibitors,P-450 Inhibitors, Cytochrome

Related Publications

Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
August 2002, Archives of pharmacal research,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
June 2005, Leukemia research,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
December 1999, Biological & pharmaceutical bulletin,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
November 2001, Acta pharmacologica Sinica,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
December 2006, International journal of biomedical science : IJBS,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
May 1999, Journal of cellular biochemistry,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
April 1997, Leukemia,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
March 2009, Free radical biology & medicine,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
June 1989, Biochemical and biophysical research communications,
Carolina C Sánchez-Martín, and Alberto Dávalos, and Covadonga Martín-Sánchez, and Gema de la Peña, and Carlos Fernández-Hernando, and Miguel A Lasunción
May 1990, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
Copied contents to your clipboard!